{"id":"https://openalex.org/W2107589145","doi":"https://doi.org/10.1177/0091270002250602","title":"Pharmacokinetics of Rosiglitazone in Patients with Varying Degrees of Renal Insufficiency","display_name":"Pharmacokinetics of Rosiglitazone in Patients with Varying Degrees of Renal Insufficiency","publication_year":2003,"publication_date":"2003-03-01","ids":{"openalex":"https://openalex.org/W2107589145","doi":"https://doi.org/10.1177/0091270002250602","mag":"2107589145","pmid":"https://pubmed.ncbi.nlm.nih.gov/12638393"},"language":"en","primary_location":{"id":"doi:10.1177/0091270002250602","doi":"https://doi.org/10.1177/0091270002250602","is_oa":false,"landing_page_url":"https://doi.org/10.1177/0091270002250602","pdf_url":null,"source":{"id":"https://openalex.org/S146237847","display_name":"The Journal of Clinical Pharmacology","issn_l":"0021-9754","issn":["0021-9754","0091-2700","0095-9863","1552-4604","2375-0839","2375-0928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5075240698","display_name":"Martha C. Chapelsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Martha C. Chapelsky","raw_affiliation_strings":["GlaxoSmithKline, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939, USA","Clinical Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939, USA","institution_ids":["https://openalex.org/I4210114143"]},{"raw_affiliation_string":"Clinical Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047615747","display_name":"Kathleen Thompson Culkin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathleen Thompson\u2010Culkin","raw_affiliation_strings":["Clinical Pharmacology Unit, GlaxoSmithKline, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology Unit, GlaxoSmithKline, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023992955","display_name":"Ann K. Miller","orcid":"https://orcid.org/0000-0002-2098-3193","observed_orcids":["https://orcid.org/0000-0002-2098-3193"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann K. Miller","raw_affiliation_strings":["Clinical Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034922033","display_name":"Marshall R. Sack","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093891","display_name":"Austin Diagnostic Clinic","ror":"https://ror.org/00k20np13","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210093891"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marshall Sack","raw_affiliation_strings":["Center for Clinical Research of the Austin Diagnostic Clinic, Austin, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Clinical Research of the Austin Diagnostic Clinic, Austin, Texas","institution_ids":["https://openalex.org/I4210093891"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111914294","display_name":"Robert A. Blum","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Blum","raw_affiliation_strings":["Clinical Pharmacokinetics Laboratory, Buffalo, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacokinetics Laboratory, Buffalo, New York","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113545845","display_name":"Martin I. Freed","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin I. Freed","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5075240698"],"corresponding_institution_ids":["https://openalex.org/I4210114143"],"apc_list":{"value":4150,"currency":"USD","value_usd":4150},"apc_paid":null,"fwci":3.7901,"has_fulltext":false,"cited_by_count":78,"citation_normalized_percentile":{"value":0.93977563,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"43","issue":"3","first_page":"252","last_page":"259"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.45410001277923584,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.45410001277923584,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.24120000004768372,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.07100000232458115,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rosiglitazone","display_name":"rosiglitazone","score":1.0},{"id":"https://openalex.org/keywords/kidney-failure","display_name":"renal failure","score":0.9139999747276306},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9509999752044678},{"id":"https://openalex.org/keywords/creatinine-clearance","display_name":"creatinine clearance","score":0.8610000014305115},{"id":"https://openalex.org/keywords/protein-binding","display_name":"protein binding","score":0.6909999847412109},{"id":"https://openalex.org/keywords/unbound-fraction","display_name":"unbound fraction","score":0.734000027179718},{"id":"https://openalex.org/keywords/dose-adjustment","display_name":"dose adjustment","score":0.8149999976158142},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7329999804496765},{"id":"https://openalex.org/keywords/thiazolidinediones","display_name":"thiazolidinediones","score":0.7440000176429749},{"id":"https://openalex.org/keywords/drug-clearance","display_name":"drug clearance","score":0.49000000953674316}],"concepts":[{"id":"https://openalex.org/C2780152017","wikidata":"https://www.wikidata.org/wiki/Q424771","display_name":"Rosiglitazone","level":3,"score":0.899369478225708},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7750833630561829},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7724881172180176},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.6939035654067993},{"id":"https://openalex.org/C159641895","wikidata":"https://www.wikidata.org/wiki/Q108377937","display_name":"Renal function","level":2,"score":0.6441647410392761},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.548848032951355},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.478250652551651},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4679167568683624},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4581214189529419},{"id":"https://openalex.org/C2779978075","wikidata":"https://www.wikidata.org/wiki/Q202301","display_name":"Dialysis","level":2,"score":0.44764280319213867},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.058058857917785645}],"mesh":[{"descriptor_ui":"D000077154","descriptor_name":"Rosiglitazone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003404","descriptor_name":"Creatinine","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D051437","descriptor_name":"Renal Insufficiency","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D051437","descriptor_name":"Renal Insufficiency","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1177/0091270002250602","doi":"https://doi.org/10.1177/0091270002250602","is_oa":false,"landing_page_url":"https://doi.org/10.1177/0091270002250602","pdf_url":null,"source":{"id":"https://openalex.org/S146237847","display_name":"The Journal of Clinical Pharmacology","issn_l":"0021-9754","issn":["0021-9754","0091-2700","0095-9863","1552-4604","2375-0839","2375-0928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:12638393","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12638393","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical pharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":17,"referenced_works":["https://openalex.org/W1506883618","https://openalex.org/W1550111394","https://openalex.org/W1918439017","https://openalex.org/W1968159865","https://openalex.org/W1971329752","https://openalex.org/W2027107698","https://openalex.org/W2036045723","https://openalex.org/W2041391173","https://openalex.org/W2048005191","https://openalex.org/W2056726092","https://openalex.org/W2078089300","https://openalex.org/W2109510102","https://openalex.org/W2140937253","https://openalex.org/W2335922553","https://openalex.org/W2340948203","https://openalex.org/W2409443295","https://openalex.org/W4406057004"],"related_works":["https://openalex.org/W2119158601","https://openalex.org/W2160353091","https://openalex.org/W1596678070","https://openalex.org/W2069759961","https://openalex.org/W2066657834","https://openalex.org/W2800713917","https://openalex.org/W2076460041","https://openalex.org/W2315388393","https://openalex.org/W2006239559","https://openalex.org/W1986550874"],"abstract_inverted_index":{"This":[0],"study":[1],"investigated":[2],"the":[3,12,138,184,213,227],"effect":[4],"of":[5,8,14,75,108,189,215,224,230],"varying":[6],"degrees":[7],"renal":[9,31,39,48,119,207,241],"insufficiency":[10,32,40,49,134,152],"on":[11,249],"pharmacokinetics":[13,107,214],"rosiglitazone.":[15,76,225],"Subjects":[16],"were":[17,67,82,92,130,142,195,201],"stratified":[18],"by":[19,95,114],"estimated":[20],"creatinine":[21],"clearance:":[22],"normal":[23,139,185],"(>":[24],"80":[25],"mL/min;":[26,34,42,57],"n":[27,35,43,58],"=":[28,36,44,55,59],"12),":[29],"mild":[30,190],"(60-80":[33],"15),":[37],"moderate":[38,192],"(30-59":[41],"18),":[45],"and":[46,64,78,89,101,179],"severe":[47,118,151,203],"not":[50,111,143,210,233],"requiring":[51],"dialysis":[52],"(<":[53],"or":[54,117,191,217],"29":[56],"12).":[60],"Plasma":[61],"rosiglitazone":[62,109,219,231],"concentrations":[63],"protein":[65],"binding":[66],"determined":[68],"after":[69],"a":[70,154,171,221],"single":[71,222],"oral":[72],"8-mg":[73],"dose":[74,223,229,244],"Total":[77],"unbound":[79,127,218],"pharmacokinetic":[80],"parameters":[81],"generated":[83],"using":[84],"noncompartmental":[85],"methods.":[86],"AUC,":[87],"Cmax,":[88],"t1/2":[90],"data":[91],"analyzed":[93],"separately":[94],"ANOVA":[96],"to":[97,137,145,162,173,183,235],"provide":[98],"point":[99],"estimates":[100],"corresponding":[102],"95%":[103],"confidence":[104],"intervals.":[105],"The":[106,187],"was":[110],"markedly":[112,211],"affected":[113],"mild,":[115],"moderate,":[116],"insufficiency.":[120],"Slight":[121],"increases":[122],"(approximately":[123],"10%-20%)":[124],"in":[125,157,165,170,238],"mean":[126,158,176],"AUC0-infinity":[128,178],"values":[129,181],"observed":[131],"for":[132,197],"each":[133],"group":[135,140],"compared":[136],"but":[141],"considered":[144],"be":[146,236,247],"clinically":[147],"relevant.":[148],"Patients":[149],"with":[150,240],"exhibited":[153],"38%":[155],"increase":[156,164],"fraction":[159],"unbound,":[160],"leading":[161],"an":[163],"total":[166,177,216],"clearance,":[167],"which":[168],"resulted":[169],"19%":[172],"24%":[174],"lower":[175],"Cmax":[180],"relative":[182],"group.":[186],"rates":[188],"adverse":[193,204],"events":[194],"similar":[196],"all":[198],"groups;":[199],"there":[200],"no":[202],"events.":[205],"Impaired":[206],"function":[208],"does":[209,232],"alter":[212],"following":[220],"Therefore,":[226],"starting":[228],"need":[234],"adjusted":[237],"patients":[239],"impairment.":[242],"Subsequent":[243],"adjustments":[245],"should":[246],"based":[248],"individual":[250],"patient":[251],"response.":[252]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}